ArticleBMC pulmonary medicine2026
Decoding the shared genetic liability of lower respiratory tract infections via genomic structural equation modeling.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLower respiratory tract infections (LRTI), including pneumonia, tuberculosis, and COVID-19, share overlapping clinical features and risk factors, yet their common genetic architecture remains poorly understood.
methodsWe applied genomic structural equation modeling (Genomic SEM) to dissect the shared genetic susceptibility among seven LRTI-related phenotypes using large-scale GWAS summary statistics. Multivariate GWAS (mvGWAS) was performed to identify variants associated with the latent LRTI factor. Post-GWAS analyses included Bayesian fine-mapping, transcriptome-wide association studies, MAGMA analysis, pathway enrichment, and cell-type specific heritability partitioning.
resultsA single latent factor model demonstrated excellent fit, confirming substantial genetic overlap across LRTI phenotypes. The mvGWAS identified 5,469 genome-wide significant variants, including 3,705 associations uniquely identified at the latent-factor level. Fine-mapping prioritized high-confidence causal variants at CAMK2D, NFKB1, CNTN5 and PARK2 loci, implicating calcium signaling, NF-κB-mediated inflammation, neuroimmune regulation, and mitochondrial quality control. TWAS highlighted TLK2, NUDT6, and PKN2 as key transcriptional regulators involved in chromatin homeostasis and inflammasome modulation. MAGMA identified RPL18A, HLA-DRB1, HLA-DQB1, and PTPN6, underscoring roles of ribosomal function, antigen presentation, and immune cell signaling. Pathway analysis revealed enrichment in coagulation cascades, while cell type analysis suggested involvement of hematopoietic progenitors and myeloid lineages.
conclusionsThis study provides the first comprehensive genetic framework for shared LRTI susceptibility, revealing convergent biological pathways spanning inflammation, mitochondrial homeostasis, antigen presentation, and coagulation. These findings offer candidate targets for host-directed therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.